Huberman LabHow Your Brain’s Reward Circuits Drive Your Choices | Dr. Robert Malenka
Andrew Huberman and Robert Malenka on dopamine, Serotonin, And Social Bonds: How Reward Shapes Behavior.
In this episode of Huberman Lab, featuring Andrew Huberman and Robert Malenka, How Your Brain’s Reward Circuits Drive Your Choices | Dr. Robert Malenka explores dopamine, Serotonin, And Social Bonds: How Reward Shapes Behavior Andrew Huberman interviews psychiatrist and neuroscientist Dr. Robert Malenka about how the brain’s reward and social circuits work, with a focus on dopamine, serotonin, and oxytocin.
At a glance
WHAT IT’S REALLY ABOUT
Dopamine, Serotonin, And Social Bonds: How Reward Shapes Behavior
- Andrew Huberman interviews psychiatrist and neuroscientist Dr. Robert Malenka about how the brain’s reward and social circuits work, with a focus on dopamine, serotonin, and oxytocin.
- They explain how the dopamine system evolved to tag experiences as important, driving learning, motivation, addiction, and social behavior, and how context and plasticity radically reshape its function over time.
- Malenka describes addiction as drug‑driven hijacking of normal reward learning, discusses individual vulnerability, and shows how drugs like MDMA expose distinct roles for dopamine versus serotonin in reinforcement and social connection.
- The conversation extends to social reward, empathy, autism spectrum disorder, and emerging psychedelic therapies, emphasizing both scientific promise and serious cautions around over‑hyping or unsafe use.
IDEAS WORTH REMEMBERING
5 ideasDopamine marks importance and salience, not just pleasure
Dopamine neurons in the ventral tegmental area (VTA) project to the nucleus accumbens and other regions to signal that something in the environment is important—not merely pleasurable. They fire during highly rewarding events (food, sex, drugs) but also during aversive or painful events. This signal boosts arousal and memory encoding, increasing the probability that we repeat—or avoid—certain behaviors in the future.
Addictive liability depends on both amount and speed of dopamine
The risk that a drug becomes addictive (“addictive liability”) scales with how much dopamine it releases in the nucleus accumbens and how rapidly that release occurs. Route of administration is critical: smoking or injecting cocaine or methamphetamine causes an almost instantaneous, massive dopamine surge compared to snorting or oral use, dramatically increasing compulsive use risk. Single drug exposures can induce plastic changes in reward circuits lasting days to weeks, and repeated use amplifies and prolongs these changes.
Wanting and liking can diverge, explaining compulsive but unenjoyable use
Drugs and rewarding behaviors can become powerfully reinforcing even when they stop feeling good. Malenka highlights the behavioral distinction: ‘reinforcing’ means a stimulus increases the probability of repeating the behavior; ‘rewarding’ means it actually feels good. With addiction, cravings (wanting) often persist or intensify even as subjective pleasure (liking) declines—people can “hate it and still want to do it again.”
Reward circuits are highly plastic and context‑dependent
The same cue can flip from appetitive to aversive depending on recent history—Huberman’s Thanksgiving example: turkey and pie smells are enticing before the meal and repulsive afterward. This flexibility arises because dopamine and accumbens neurons receive inputs from hippocampus (memory), amygdala (emotion), prefrontal cortex (rules, planning), and sensory areas. Prior experiences with a cue (e.g., donuts, drugs, people) reshape how reward circuits respond to that cue in the future.
Social interaction is a major natural activator of reward circuitry
Non‑aggressive, non‑sexual social interactions are strongly reinforcing in social species and engage the same reward circuitry as food and drugs. Malenka’s lab and others show that oxytocin and serotonin act within the nucleus accumbens and VTA to enhance social reward, and that dopamine is released during positive social contact. Evolutionarily, social reward supports mating, cooperative child‑rearing, protection from predators, and emotional buffering.
WORDS WORTH SAVING
5 quotesIt’s not an accident that sugary, high‑fat foods are highly reinforcing. There has to be a mechanism in the brain that tells us that.
— Dr. Robert Malenka
A single administration of a drug of abuse like cocaine or morphine can cause changes in reward‑circuit connections that last days to weeks.
— Dr. Robert Malenka
You can’t develop a problem with a substance if you never take it. By definition.
— Dr. Robert Malenka
Liking something means it actually feels good. Wanting means you work to get it again. And those can come apart.
— Dr. Robert Malenka
What is more important for the survival of the human species than empathy and compassion?
— Dr. Robert Malenka
QUESTIONS ANSWERED IN THIS EPISODE
5 questionsIn your mouse models, how far can you push the ‘generosity’ or ‘compassion’ behaviors—will a hungry or mildly stressed mouse still work to help another mouse, and what does that say about human trade‑offs between self‑interest and empathy?
Andrew Huberman interviews psychiatrist and neuroscientist Dr. Robert Malenka about how the brain’s reward and social circuits work, with a focus on dopamine, serotonin, and oxytocin.
Given that single cocaine exposures can induce weeks‑long plasticity in reward circuits, do you think one‑time, supervised psychedelic or MDMA sessions could induce beneficial plasticity in social or emotional circuits that are comparably long‑lasting?
They explain how the dopamine system evolved to tag experiences as important, driving learning, motivation, addiction, and social behavior, and how context and plasticity radically reshape its function over time.
You mentioned that some individuals experience alcohol as a ‘magic elixir’ from the very first drink—what specific genetic or developmental factors do you suspect make certain brains so immediately susceptible while others are relatively protected?
Malenka describes addiction as drug‑driven hijacking of normal reward learning, discusses individual vulnerability, and shows how drugs like MDMA expose distinct roles for dopamine versus serotonin in reinforcement and social connection.
If MDMA’s prosocial effects are largely serotonergic and its addictive liability largely dopaminergic, how close do you think we are to a medication that produces the social/empathic benefits without meaningful abuse potential—and what would the biggest safety concern still be?
The conversation extends to social reward, empathy, autism spectrum disorder, and emerging psychedelic therapies, emphasizing both scientific promise and serious cautions around over‑hyping or unsafe use.
In autism spectrum disorder, how confident are you that reduced social motivation is primarily a reward‑circuit issue rather than, say, sensory overload or anxiety about social cues—and how might you design experiments (in humans or animals) to disentangle those possibilities?
Chapter Breakdown
Intro, Malenka’s Background, and Scope of the Conversation
Huberman introduces Dr. Robert Malenka, outlining his seminal contributions to neuroplasticity, reward systems, addiction, social neuroscience, autism, and emerging work on psychedelics. They set expectations that the discussion will connect molecular mechanisms to everyday behaviors like motivation, addiction, and social connection.
Dopamine 101: Reward, Salience, and Evolutionary Function
Malenka explains what dopamine is, where key dopamine neurons live, and how the brain’s reward circuit works. He emphasizes that dopamine signals evolutionary importance and salience—not just pleasure—and is tightly linked with arousal and memory systems.
Context, Prefrontal Cortex, and the Flexibility of Reward
They discuss how context, internal state, and prior experience radically change how reward circuits respond to the same cue. Prefrontal cortex, hippocampus, amygdala, and sensory inputs converge on the nucleus accumbens to scale and reshape dopamine’s impact.
Addiction: Drug Kinetics, Plasticity, and Individual Vulnerability
The conversation shifts to addiction: why some drugs are more addictive than others, how kinetics of dopamine release matter, and how even single exposures can produce lasting plasticity in reward circuits. They also explore why only some users develop severe addiction.
Wanting vs. Liking, Tolerance, and 12‑Step Reframing
Malenka introduces the distinction between reinforcement (increasing behavior), reward (subjective pleasure), wanting, and liking. They connect this to clinical observations and 12‑step approaches that deliberately create reward around abstinence and sober identity.
Nicotine, Personal Anecdotes, and Hidden Reinforcement Patterns
Malenka shares a personal story about briefly smoking in Paris and still craving cigarettes in that context decades later, illustrating how powerful cue‑linked reward learning can be. They also touch on nicotine’s high addictive liability despite its social normalization.
Social Reward, Evolution, and the Role of Serotonin and Oxytocin
The focus shifts from drugs to natural social rewards. Malenka explains why his lab moved from studying addiction to social behavior, and how oxytocin and serotonin in nucleus accumbens and VTA modulate sociability. They ground social reward in evolutionary pressures.
Autism Spectrum Disorder, Social Motivation, and Terminology Nuance
They carefully discuss autism spectrum disorder (ASD), balancing respect for neurodiversity with recognition that some individuals have severe, disabling symptoms. Malenka reviews evidence that social reward processing and serotonergic systems may be altered in some forms of ASD.
Empathy and Social Transfer of Pain and Relief in Mice
Malenka describes his lab’s work on “behavioral antecedents of empathy” in mice: social transfer of pain and analgesia, and early work on generosity/compassion assays. These behaviors engage circuits also implicated in human empathy, including anterior cingulate to accumbens pathways.
MDMA, Serotonin vs. Dopamine, and Social Therapies
They dive into MDMA as a powerful probe of social and reward circuits. Malenka explains how MDMA’s stronger action on serotonin transporters—alongside dopamine—helps separate its reinforcing from its prosocial effects, and how this guides drug development for social dysfunction, including in ASD.
Psychedelics, Caution, and the Future of Therapeutic Use
In closing, Malenka shares his measured enthusiasm for psychedelic research. As a child of the 60s/70s, he sees enormous scientific and therapeutic potential but warns strongly against evangelical hype and uncontrolled use that could produce harm and backlash.
EVERY SPOKEN WORD
Install uListen for AI-powered chat & search across the full episode — Get Full Transcript
Get more out of YouTube videos.
High quality summaries for YouTube videos. Accurate transcripts to search & find moments. Powered by ChatGPT & Claude AI.
Add to Chrome